New WHO ACPA standard enables standardisation among anti-CCP2 assays, but not other ACPA assays using different antigens
Ann Rheum Dis
.
2024 Nov 14;83(12):1793-1794.
doi: 10.1136/ard-2024-226169.
Authors
Lieve Van Hoovels
1
2
,
Liesbeth E Bakker-Jonges
3
,
Dina Vara
4
,
Caroline Bijnens
5
,
Lucy Studholme
4
,
Daniela Sieghart
6
,
Bert Vander Cruyssen
7
,
Patrick Verschueren
8
,
Guenter Steiner
6
9
,
Jan G M C Damoiseaux
5
,
Xavier Bossuyt
2
10
Affiliations
1
Department of Laboratory Medicine, OLV Hospital Aast, Aalst, Belgium
[email protected]
.
2
Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
3
Reinier Haga Medical Diagnostic Center, Delft, The Netherlands.
4
Medicines and Healthcare Regulatory Agency (MHRA), Hertfordshire, UK.
5
Laboratory of Clinical Immunology, Maastricht University Medical Center, Maastricht, The Netherlands.
6
Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
7
Department of Rheumatology, OLV Hospital Aalst, Aalst, Belgium.
8
Department of Rheumatology, KU Leuven University Hospitals Leuven, Leuven, Belgium.
9
Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Vienna, Austria.
10
Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium.
PMID:
39043437
DOI:
10.1136/ard-2024-226169
No abstract available
Keywords:
Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Autoantibodies.
Publication types
Letter